Peptides DB
Research-centric peptide and protocol reference hub
Study 2 of 9Melanotan II literaturePubMed · Observational · Preclinical2024

Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress.

Chronic treatment with Semax and Melanotan II showed potential in reversing stress-induced anhedonia in rats, but the implications for human treatment remain unclear.

Read at PubMedAdd to compare

Where it sits

this study against the rest of the melanotan ii corpus
3
Preclinical
6
Observational · this one
0
Open-label
0
Randomised
0
Reviews

Summary and findings

This study investigated the effects of Semax and Melanotan II (MTII) on male Sprague-Dawley rats subjected to chronic unpredictable stress (CUS). The rats received daily intraperitoneal injections of 60 nmol/kg of body weight of either peptide or saline. The study measured body weight, hedonic status via the sucrose preference test, and hippocampal BDNF levels.

How much of this paper we could read: partial text (0.60). We had some abstract detail. Check the source for anything decisive. What this means →
Not reported in abstract.Preclinical2024

Abstract

The authors’ words, as PubMed supplied them

Current antidepressant therapy shows substantial limitations, and there is an urgent need for the development of new treatment strategies for depression. Stressful events and hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis play an important role in the pathogenesis of depression. HPA axis activity is self-regulated by negative feedback at several levels including adrenocorticotropic hormone (ACTH)-mediated feedback. Here, we investigated whether noncorticotropic synthetic analogs of the ACTH(4-10) fragment, ACTH(4-7)-Pro-Gly-Pro (Semax) and Ac-Nle4-cyclo[Asp5-His6-D-Phe7-Arg8-Trp9-Lys10]ACTH(4-10)-NH2 (Melanotan II (MTII), a potent agonist of melanocortin receptors), have potential antidepressant activity in a chronic unpredictable stress (CUS) rat model of depression. Stressed and control male adult Sprague-Dawley rats received daily intraperitoneal injections of saline or a low dose (60 nmol/kg of body weight (BW)) of Semax or MTII. Rats were monitored for BW and hedonic status, as measured in the sucrose preference test. We found that chronic treatment with Semax and MTII reversed or substantially attenuated CUS-induced anhedonia, BW gain suppression, adrenal hypertrophy and a decrease in the hippocampal levels of BDNF. In the forced swim test, no effects of the CUS procedure or peptides on the duration of rat immobility were detected. Our findings show that in the CUS paradigm, systemically administered ACTH(4-10) analogs Semax and MTII exert antidepressant-like effects on anhedonia and hippocampal BDNF levels, and attenuate markers of chronic stress load, at least in male rats. The results support the argument that ACTH(4-10) analogs and other noncorticotropic melanocortins may have promising therapeutic potential for the treatment and prevention of depression and other stress-related pathologies.

Background

The paper addresses the potential antidepressant and antistress effects of synthetic analogs of ACTH, specifically Semax and Melanotan II, in a chronic unpredictable stress model in male rats. Prior research has indicated that ACTH analogs may influence mood and stress responses, but the specific mechanisms and efficacy in this context remain under investigation. Understanding these effects could provide insights into new therapeutic avenues for stress-related disorders.

Methods

The study utilized a rodent model, specifically male rats, to assess the effects of Semax and Melanotan II under conditions of chronic unpredictable stress. The exact sample size, dosing regimen, duration of treatment, and specific outcome measures were not reported in the abstract.

Results

Not reported in abstract.

Interpretation

Without specific numeric findings or effect sizes reported, it is challenging to compare these results to existing literature or to assess the clinical significance of the findings. The use of rodent models introduces confounding factors that may limit the applicability of the results to human populations. Further studies with detailed methodologies and human data are necessary to draw meaningful conclusions.

Key findings

  • Not reported in abstract.

Limitations

  • Not reported in abstract.
  • Rodent model limits direct applicability to humans.
  • Specific dosing and outcome measures not provided.
  • Small sample size not specified.

Elsewhere in the Melanotan II corpus

CAssociation of central α-klotho with dopaminergic and melanocortin receptors on feed intake regulation in chicken.europepmc · 2026 · Not reported in abstract.AnimalCLow dose systemic AAV-exendin-4 gene therapy for Prader-Willi syndrome and dietary obesity.europepmc · 2026 · Not reported in abstract.AnimalBFive primary melanomas in situ in a patient with recent tanning bed use, melanotan exposure, and anabolic hormone use.europepmc · 2026 · n=1 · Not reported in abstract.HumanCMelanocortin receptor agonist melanotan-II microinjected in the nucleus accumbens decreases appetitive and consumptive responding for foodbiorxiv-preprint · 2022 · n=20 · Not reported in abstract.AnimalBChanges in Oral Mucosa Associated with Melanotan II Injections: A Case Report.PubMed · 2026 · Not reported in abstract.HumanDSemantic Scholar search for Melanotan IISemanticScholar